ACRV’s AI-driven AP3 platform targets precision drug development
ACRV says its AI-driven AP3 platform matches drug effects to disease pathways, validated in internal and in-licensed assets. Lead programs include phase II-B CHK1/2 inhibitor for serous endometrial cancer and phase II WEE1/PKMYT1 inhibitor.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.